Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease

This study has been terminated.
(Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns identified.)
Information provided by:
Neurogen Corporation Identifier:
First received: December 15, 2008
Last updated: August 27, 2009
Last verified: August 2009
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: October 2009
  Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)